A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

por Munster, P N, Thurn, K T, Thomas, S, Raha, P, Lacevic, M, Miller, A, Melisko, M, Ismail-Khan, R, Rugo, H, Moasser, M, Minton, S E
Publicado 2011